Abstract
Purpose
Time and out-of-pocket (OOP) costs can represent a substantial burden for cancer patients but have not been described for long-term cancer survivors. We estimated these costs, their predictors, and their relationship to financial income, among a cohort of long-term prostate cancer (PC) survivors.
Methods
A population-based, community-dwelling, geographically diverse sample of long-term (2–13 years) PC survivors in Ontario, Canada, was identified from the Ontario Cancer Registry and contacted through their referring physicians. We obtained data on demographics, health care resource use, and OOP costs through mailed questionnaires and conducted chart reviews to obtain clinical data. We compared mean annual time and OOP costs (2006 Canadian dollars) across clinical and sociodemographic characteristics and examined the association between costs and four groups of predictors (patient, disease, system, symptom) using two-part regression models.
Results
Patients' (N = 585) mean age was 73 years; 77 % were retired, and 42 % reported total annual incomes less than $40,000. Overall, mean time costs were $838/year and mean OOP costs were $200/year. Although generally low, total costs represented approximately 10 % of income for lower income patients. No demographic variables were associated with costs. Radical prostatectomy, younger age, poor urinary function, current androgen deprivation therapy, and recent diagnosis were significantly associated with increased likelihood of incurring any costs, but only urinary function significantly affected total amount.
Conclusions
Time and OOP costs are modest for most long-term PC survivors but can represent a substantial burden for lower income patients. Even several years after diagnosis, PC-specific treatments and treatment-related dysfunction are associated with increased costs.
Implications for Cancer Survivors
Time and out-of-pocket costs are generally manageable for long-term PC survivors but can be a significant burden mainly for lower income patients. The effects of PC-specific, treatment-related dysfunctions on quality of life can also represent sources of expense for patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Longo CJ, Fitch M, Deber RB, Williams AP. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer. 2006;14:1077–85.
Longo CJ, Deber R, Fitch M, Williams P, DeSouza D. An examination of cancer patients' monthly “out-of-pocket” costs in Ontario. Eur J Cancer Care. 2007;16:500–7.
Federico CA, Hsu PC, Krajden M, Yoshida EM, Bremner KE, Weiss AA, et al. Patient time costs and out-of-pocket costs in hepatitis C. Liver Int. 2012;32(5):815–25.
Mathews M, West R, Buehler S. How important are out-of-pocket costs to rural patients' cancer care decisions? Can J Rural Med. 2009;14(2):54–60.
Langa KM, Fendrick AM, Chernew ME, Kabeto MU, Paisley KL, Hayman JA. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health. 2004;7(2):186–94.
Yabroff KR, Warren JL, Knopf K, Davis WW, Brown ML. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43(7):640–8.
Yabroff KR, Kim Y. Time costs associated with informal care giving for cancer survivors. Cancer. 2009;115(18 Suppl):4362–73.
Huang J, Zhou S, Groome P, Tyldesley S, Zhang-Solomans J, Mackillop WJ. Factors affecting the use of palliative radiotherapy in Ontario. J Clin Oncol. 2001;19(1):137–44.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
Krahn MD, Zagorski B, Laporte A, Alibhai SMH, Bremner KE, Tomlinson G, et al. Healthcare costs associated with prostate cancer: estimates from a population-based study. Br J Urol Int. 2010;105(3):338–40.
Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-medicare data. Content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8, Supplement):IV-3–18.
Hall S, Schulze K, Groome P, McKillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario cancer registry. J Clin Epidemiol. 2006;59:67–76.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.
Litwin MS, Hays RD, Fink A, et al. The UCLA prostate cancer index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.
Van Buuren S, Oudshoorn CGM. Flexible multivariate imputation by MICE. Leiden: TNO Preventie en Gezondheid, TNO/VGZ/PG 99.054, 1999.
Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. Br Med J. 2009;338:b2393.
Jones AM, Rice N, Bago d’Uva T, Balia S. Applied health economics. London: Routledge; 2007.
R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria.
SAS Inc. SAS 9.1.3 for Windows. Cary, N.C., USA.
Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Qualily Life Res. 2007;16:509–22.
Krahn MD, Ritvo P, Irvine J, Tomlinson G, Bremner KE, Bezjak A, et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41:153–64.
Pisu M, Azuero A, McNees P, Burkhardt J, Benz R, Meneses K. The out of pocket cost of breast cancer survivors: a review. J Cancer Survivorship. 2010;4(3):202–9.
Jayadevappa R, Schwartz JS, Chhatre S, Gallo JJ, Wein AJ, Malkowicz SB. The burden of out-of-pocket and indirect costs of prostate cancer. Prostate. 2010;70(11):1255–64.
Taylor AKL, Luta G, Miller AB, Church TR, Kelly SP, Muenz LR, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30(22):2768–75.
Krahn MD, Bremner KE, Alibhai SMH, Ni A, Tomlinson G, Laporte A, Naglie G. A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada. Quality of Life Research. 2013. doi:10.1177/0272989X13493970.
Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96(17):1322–30.
Mickevičienė A, Vanagas G, Ulys A, Jievaltas M, Smailytė G, Padaiga Ž. Factors affecting health-related quality of life in prostate cancer patients. Scan J Urol Nephrol. 2012;46(3):180–7.
Lauzier S, Maunsell E, Drolet M, Coyle D, Hébert-Croteau N. Validity of information obtained from a method for estimating cancer costs from the perspective of patients and caregivers. Qual Life Res. 2010;19(2):177–89.
Acknowledgments
This work was supported by a project grant from the Canadian Institutes for Health Research (CIHR, #53114), an Investigator Award from the CIHR (Dr. Krahn), the F. Norman Hughes Chair in Pharmacoeconomics (Dr. Krahn), and a Research Scientist Award from the National Cancer Institute of Canada (Dr. Alibhai).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(DOC 79 kb)
Rights and permissions
About this article
Cite this article
de Oliveira, C., Bremner, K.E., Ni, A. et al. Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada. J Cancer Surviv 8, 9–20 (2014). https://doi.org/10.1007/s11764-013-0305-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11764-013-0305-7